Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)

Matsumoto, Koji; Katsumata, Noriyuki; Shibata, Taro; Saitou, Motoaki; Yunokawa, Mayu; Takano, Tadao; Nakamura, Kenichi; Kamura, Toshiharu; Konishi, Ikuo

doi:10.1016/j.ygyno.2014.10.026

Cited by 8 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six included studies encompassing 718 patients reported on the prevalence of VTE in ovarian cancer patients undergoing chemotherapy [ 40 , 79 , 82 , 96 , 115 , 121 ]. The meta-analysis revealed a pooled estimated prevalence of 8%, ranging from 5% to 12% (ES 8%; 95% CI 5–12%; z = 7.47; p = 0.02) ( Table 4 and Supplemental SI Figure S9 ).…”

Section: Resultsmentioning

confidence: 99%

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Sun

Bhaskar

2022

Diagnostics

View full text Add to dashboard Cite

Objective: Venous thromboembolism (VTE) is a life-threatening complication that may exacerbate cancer prognosis. Whilst some studies indicate an increased risk of VTE in cancer patients undergoing chemotherapy, the prevalence estimates on the pooled prevalence of VTE in cancer patients undergoing chemotherapy are not known. This study aims to calculate the pooled prevalence of VTE in chemotherapy-treated cancer patients. Methods: Studies on VTE occurrence in cancer patients undergoing chemotherapy were retrieved after database search. The terms used included “cancer”, “chemotherapy”, and “venous thromboembolism”. A random-effects meta-analysis was conducted to obtain a pooled estimate of VTE prevalence in cancer patients undergoing chemotherapy. Results: A total of 102 eligible studies involving 30, 671 patients (1773 with VTE, 28, 898 without) were included in the meta-analysis. The pooled estimate of VTE prevalence was found to be 6%, ranging from 6 to 7% (ES 6%; 95% CI 6–7%; z = 18.53; p < 0.001). Conclusions: The estimated pooled prevalence rate of VTEs was 6% in cancer patients undergoing CRT, which was higher than the overall crude prevalence rate (5.78%). Comprehensive cancer care should consider stratified VTE risk assessment based on cancer phenotype, given that certain phenotypes of cancer such as bladder, gastric and ovarian posing particularly high risks of VTE.

show abstract

Section: Resultsmentioning

confidence: 99%

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Sun

Bhaskar

2022

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Therefore, the authors did not recommend this strategy outside because of adverse events. [30] Fortunately, the combination of oral etoposide with apatinib showed a promising efficacy with a 54% ORR and a manageable safety profile. [31] Thus, oral etoposide plus apatinib might be a potential regimen for previously platinum treated OC patients amid the epidemic.…”

Section: Oral Etoposide Combined With Apatinib Ovarian Cancermentioning

confidence: 99%

Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic

Bi-cheng¹,

Xiao²

2022

jbyyj

View full text Add to dashboard Cite

The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since December 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies of cancer patients were considerably delayed. Up to now, cancer patients throughout the world directly encounter similar obstacles. For patients who have the right to choose chemotherapeutic regimens with different administration routes, oral drugs can be considered to be applied. In this mini-review, oral chemotherapeutic drugs were compared with intravenous drugs in seven types of tumors. Accordingly, we intended to provide useful suggestions for clinicians to balance the benefits and risks of oral against intravenous chemotherapies and to choose properly substituted oral chemotherapeutic regimens for cancer patients amid the coronavirus disease 2019 (COVID-19) pandemic.

show abstract

Treatment of Recurrent Epithelial Ovarian Cancer

Yanazume

Kobayashi

2017

Comprehensive Gynecology and Obstetrics

View full text Add to dashboard Cite

Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemotherapy. However, the prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy induces complete and partial response in up to 80% of patients with about a 25% pathological complete remission rate, recurrences occur in the majority of patients. The role of surgery in recurrent disease has been recently studied and many patients can receive an optimal secondary cytoreduction. Most of the recurrent patients are subject to a number of treatment regimens that, although palliative in nature, are also able to prolong survival. Important results have been obtained in particular in platinum-sensitive recurrent disease where a platinum-based chemotherapy is able to prolong progression-free survival and overall survival. Overall, our armamentarium for the treatment of progressive or recurrent ovarian cancer is significantly richer than in the past, and in many patients it is possible to achieve our goal of controlling the chronic behavior of the disease.

show abstract

Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)

Cited by 8 publications

References 26 publications

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis

Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic

Treatment of Recurrent Epithelial Ovarian Cancer

Contact Info

Product

Resources

About